Impressive Achievements for 9 Consecutive Years
2024 marks the 9th consecutive year of Bidiphar’s presence in the ranking of Vietnam’s most reputable pharmaceutical companies. The ranking is based on three main criteria: Financial Capacity (based on the latest financial statements), Media Reputation – assessed through Media Coding, encoding articles related to the company in reputable media outlets; and a survey of relevant entities, including customers, partners, and industry experts, conducted in October-November 2024.
This success reflects the company’s efforts in product development, market expansion, and solidifying its position in the healthcare industry.
Bidiphar currently boasts over 400 medicinal products licensed by the Ministry of Health, distributed in 99% of hospitals nationwide, and nearly 20,000 domestic pharmacies. The enterprise focuses on three key product lines: cancer treatment drugs, antibiotics, and blood and peritoneal dialysis solutions.
In the cancer treatment drug segment, Bidiphar possesses 16 active substances with two dosage forms: injectable and freeze-dried injectable drugs. This segment accounts for 20% of total revenue, leading the domestic market share (second only to five foreign enterprises).
Regarding antibiotics, Bidiphar owns 37 active substances, 82 products, and four dosage forms. This segment contributes approximately 28% of total revenue, holding 2.05% of the national antibiotic market share.
The blood and peritoneal dialysis solutions have a low competition rate, accounting for 10% of revenue and effectively serving the treatment needs of domestic patients.
Strategic Vision for 2030
Bidiphar aims to enter the top 3 most reputable pharmaceutical companies in Vietnam by 2030. Simultaneously, the company is working towards completing GMP-EU standards for three critical production lines: cancer treatment drugs, small-volume sterile drugs, and Non-Betalactam injectables.
Bidiphar: Growth Expectations from a Solid Foundation
“Imexpharm Hosts Investor and Analyst Conference: A Mid-Year Review of 2024”
On August 5, 2024, Imexpharm hosted an Investor and Analyst Conference, attended by over 50 representatives from investment funds, financial institutions, securities companies, and both domestic and international media outlets.
The Golden Land Grab: Đà Nẵng’s Decade-Long Struggle with Abandoned Projects
A slew of large-scale projects in Da Nang have been stagnant for over a decade despite receiving investment certificates and investment policy approvals from the city. A number of these projects have even ceased operations.
Hanwha Life Vietnam: A Leading Force in the Top 10 Most Reputable Insurance Companies
For the 8th consecutive year, Hanwha Life Vietnam has been recognized in the prestigious “Top 10 Reputable Life Insurance Companies” ranking, as announced by Vietnam Report. This esteemed accolade underscores the company’s unwavering commitment to upholding the interests of its customers, with trust and integrity at the forefront of its values.
